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model analyzed the relationship between Cmin,ss and safety 
outcomes.
Results Pharmacokinetic samples from 906 patients were 
included in exposure–efficacy analyses; samples from 905 
patients were included in exposure–safety analyses. A 
significant association was identified between Cmin,ss and 
overall survival (OS) and progression-free survival (PFS) 
(p < 0.0001 for both). This association remained significant 
after adjusting for baseline factors associated with OS or 
PFS (p < 0.0001 for both). Median OS was 11.5, 12.9, 16.4, 
and 16.7, and 12.4 months for ramucirumab Cmin,ss Q1, Q2, 
Q3, Q4, and placebo group, respectively. Median PFS was 
5.4, 4.6, 6.8, 8.5, and 5.2 months for ramucirumab Cmin,ss 
Q1, Q2, Q3, Q4, and placebo group, respectively. The risk 
of Grade ≥3 neutropenia was associated with an increase in 
ramucirumab exposure.
Conclusions Exploratory exposure–response analy-
ses suggested a positive relationship between efficacy 
Abstract 
Purpose To characterize ramucirumab exposure–response 
relationships for efficacy and safety in patients with meta-
static colorectal cancer (mCRC) using data from the RAISE 
study.
Methods Sparse pharmacokinetic samples were collected; 
a population pharmacokinetic analysis was conducted. Uni-
variate and multivariate Cox proportional hazards models 
analyzed the relationship between predicted ramucirumab 
minimum trough concentration at steady state (Cmin,ss) and 
survival. Kaplan–Meier analysis was used to evaluate sur-
vival from patients in the ramucirumab plus folinic acid, 
5-fluorouracil, and irinotecan (FOLFIRI) treatment arm 
stratified by Cmin,ss quartiles (Q). An ordered categorical 
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and ramucirumab exposure with manageable toxicities in 
patients from the RAISE study with mCRC over the ranges 
of exposures achieved by a dose of 8 mg/kg every 2 weeks 
in combination with FOLFIRI.
Keywords Ramucirumab · Exposure–response · 
Colorectal cancer · Second line · FOLFIRI
Introduction
Colorectal carcinoma (CRC) is the third leading cause 
of cancer worldwide [1] and ranks fourth among leading 
causes of cancer deaths worldwide [2]. Conventional sys-
temic therapy for CRC includes fluoropyrimidine-based 
regimens alone or in combination with irinotecan or oxali-
platin [3–7]. The development of agents targeting the epi-
dermal growth factor receptor (EGFR) and angiogenic path-
ways has provided additional treatment options. Vascular 
endothelial growth factor (VEGF) and VEGF receptor-2 
(VEGFR-2)-mediated signaling and angiogenesis are impor-
tant in CRC tumor growth and are established therapeutic 
targets. Ramucirumab is a human IgG1 monoclonal anti-
body that specifically binds to the extracellular domain of 
VEGFR-2 with high affinity, preventing binding of VEGF-
A, C, and D ligands and receptor activation [8]. The safety 
and efficacy of ramucirumab in combination with second-
line folinic acid, 5 fluorouracil, and irinotecan (FOLFIRI) 
in patients with metastatic CRC that progressed during or 
after first-line therapy with bevacizumab, oxaliplatin, and a 
fluoropyrimidine were evaluated in a randomized, double-
blind, placebo-controlled phase III trial (RAISE) [9]. On 
Day 1 of each 2-week cycle, patients received either 8 mg/
kg ramucirumab or placebo as a 60 min intravenous infu-
sion, followed by the FOLFIRI regimen. The RAISE trial 
demonstrated a statistically significant survival benefit for 
patients treated with ramucirumab plus FOLFIRI versus 
placebo plus FOLFIRI with a median overall survival (OS) 
of 13.3 months (95% confidence interval [CI] 12.4–14.5) 
for patients in the ramucirumab group versus 11.7 months 
(95% CI 10.8–12.7) for the placebo group (hazard ratio [HR] 
0.844, 95% CI 0.730–0.976; log-rank p = 0.0219). Ramu-
cirumab plus FOLFIRI was well tolerated and the adverse 
events were considered manageable [9].
All drugs have dose effect curves, a threshold concen-
tration below which they are ineffective, a concentration 
where effect has reached a maximum plateau and between 
these extremes a range where increasing exposure increases 
effectiveness. The ‘exposure–response’ phenomenon occurs 
in the range of concentrations (exposure) where increasing 
exposure correlates with increasing effect. The phenomenon 
of exposure–response is seen with many antibodies in the 
treatment of cancer, including ipilimumab in melanoma 
[10], trastuzumab emtansine in breast cancer [11], rituxi-
mab in the treatment of low-grade B cell malignancies, 
and rilotumumab in gastric cancer [12]. Analyses of the 
exposure–response relationship of ramucirumab in patients 
with gastric cancer (REGARD and RAINBOW trials) and 
non-small cell lung cancer (REVEL trial) have previously 
been reported [13, 14]. In both RAINBOW and REGARD, 
higher exposure to ramucirumab was associated with longer 
OS and progression-free survival (PFS) for gastric cancer 
patients. In REVEL, higher exposure to ramucirumab was 
associated with longer OS and PFS for non-small cell lung 
cancer patients.
The objective of this exploratory analysis was to deter-
mine whether there is an exposure–response relationship for 
ramucirumab in patients with advanced CRC enrolled in the 
RAISE trial.
Materials and methods
The details of the RAISE trial including patient eligibility, 
trial design, randomization, dose administration, clinical 
outcome definitions, and statistical analyses have been pre-
viously published [9]. Each center’s institutional review 
board or independent ethics committee approved the study. 
The trial followed the principles of the Declaration of Hel-
sinki and the Good Clinical Practice Guidelines of the 
International Conference on Harmonisation. All patients 
provided written informed consent. To summarize, eligi-
ble patients included those with pathologically confirmed 
metastatic CRC, known KRAS exon 2 mutation status 
(mutant or wild-type), and an Eastern Cooperative Oncol-
ogy Group performance status (ECOG PS) score of 0 or 
1 with disease progression during or within 6 months of 
the last dose of first-line combination therapy with bevaci-
zumab, oxaliplatin, and a fluoropyrimidine for metastatic 
disease. Patients were randomized (1:1) to receive on Day 
1 of each 2-week cycle either 8 mg/kg ramucirumab or 
placebo as a 60 min intravenous infusion, followed by 
the FOLFIRI regimen (180 mg/m2 intravenous irinotecan 
given over 90 min followed by or concurrent with 400 mg/
m2 intravenous leucovorin given over 120 min, followed 
by 400 mg/m2 fluorouracil given as an intravenous bolus 
over 2–4 min then 2400 mg/m2 given as a continuous infu-
sion over 48 h; Fig. 1). Dose modifications were permit-
ted for ramucirumab in the setting of non-life-threatening 
and reversible Grade 3 clinical adverse events (AEs; for 
example, fever) considered to be at least possibly related 
to investigational product and that resolved to Grade ≤1 or 
pre-treatment baseline within 1 treatment cycle (approxi-
mately 2 weeks). FOLFIRI modifications were allowed 
for each component and were based on toxicities observed 
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and graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI-
CTCAE) v4.0.
The primary endpoint was OS, defined as the time from 
randomization to death from any cause. Key secondary 
endpoints included PFS (defined as time from randomiza-
tion to progressive disease or death, whichever occurred 
first), the proportion of patients who achieved an objec-
tive response (defined as complete response or partial 
response), pharmacokinetic (PK) parameters of ramu-
cirumab, and safety.
Pre-dose and 1-h post-infusion PK samples to determine 
ramucirumab serum concentration were collected at the fol-
lowing timepoints per study protocol: Day 1 of Cycles 3, 5, 
9, 13, and 17. Due to the timing of PK sample collection, 
only patients from both treatment arms who had non-missing 
concentration data and who did not die or discontinue prior 
to Day 1 Cycle 3 were included in the exposure–response 
analysis. The patients included in the exposure–response 
analyses are a non-random subset of the intent-to-treat (ITT) 
population.
Serum ramucirumab concentration was determined using 
a validated enzyme-linked immunosorbent assay (ELISA) at 
Intertek Pharmaceutical Services (San Diego, CA, USA). 
A population PK model was developed using a nonlinear 
mixed-effect modeling approach (NONMEM 7.3 [Icon, Elli-
cott City, MD]) and in accordance with the U.S. Food and 
Drug Administration (FDA) Guidance for Industry on Pop-
ulation Pharmacokinetics [15, 16]. Population PK model-
predicted minimum concentration at steady state (Cmin,ss) 
was used to assess the exposure–response relationship.
Exposure–efficacy analysis
The exposure–efficacy analysis was conducted using  SAS® 
version 9.1.2 or higher. Univariate and multivariate Cox pro-
portional hazards models were used to evaluate the relation-
ship between ramucirumab exposure and efficacy endpoints 
(OS and PFS). Data for the ramucirumab plus FOLFIRI 
treatment arm were separated into four quartiles (Q) based 
on the exposure parameter of interest, Cmin,ss. Kaplan–Meier 
analyses were performed for OS and PFS with data from 
patients in the ramucirumab plus FOLFIRI arm stratified 
according to Cmin,ss quartile; each quartile was compared 
with the data from patients in the placebo plus FOLFIRI 
(control) arm. A multivariate Cox model adjusted for base-
line covariates was used to estimate the HR for each quar-
tile versus the control arm. Stepwise Cox regression, with 
entry p value = 0.05 and exit p value = 0.10, selected the 
baseline factors prognostic for OS or PFS. These significant 
factors were used to adjust the final model for evaluating 
exposure–efficacy relationships. An additional matched 
case–control analysis for OS was explored to adjust for the 
potential imbalances in important prognostic factors between 
treatment arms within each exposure quartile group [17]. In 
this analysis, the case groups are the four exposure quartiles 
of Cmin,ss in the ramucirumab plus FOLFIRI arm. For every 
patient in each case group, a matched control patient was 
identified from all patients receiving placebo plus FOLFIRI, 
through a matching scheme based on the six significant 
potential prognostic factors identified in the stepwise Cox 
regression analysis and two additional covariates with the 
largest baseline imbalance in the subset of patients for this 
analysis (sex and prior bevacizumab use—composite sub-
group). The two additional factors were selected based on a 
stepwise logistic regression of treatment arm assignment on 
the same pool of covariates in the stepwise Cox regression, 
and stepwise selection using entry and exit p values of 0.2 
(since randomization is supposed to make treatment assign-
ment to be independent of baseline variables, a larger sig-
nificance level was used to pick up any imbalanced factors 
due to chance). Missing values in any of the matching factors 
excluded the patients from the matched case–control study.
Exposure–safety analysis
Ordered categorical and logistic regression models were 
developed to explore the relationship between ramucirumab 
exposure (Cmin,ss) and the safety endpoints. Safety endpoints 
for exposure–safety analysis were the three most common 
Grade ≥3 treatment-emergent adverse events (TEAEs) in the 
ITT population occurring in ≥5% of patients in the ramu-
cirumab plus FOLFIRI arm, with a difference in incidence 
rate between the ramucirumab arm and the placebo arm 
of ≥2%. Neutropenia, hypertension, and fatigue were the 
Fig. 1  RAISE study design aIrinotecan: 180 mg/m2; Folinic acid: 
400 mg/m2; 5-flurouracil: 400 mg/m2 bolus followed by 400 mg/
m2 given as a continuous infusion over 48 hours FOLFIRI, folinic 
acid, 5-fluorouracil, and irinotecan; IG immunogenicity; IV intrave-
nous; ORR objective response rate; PFS progression-free survival; 
PK pharmacokinetics; PRO patient-reported outcomes; RAM ramu-
cirumab
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selected endpoints for exposure–safety analysis based on 
these criteria. For this analysis, neutropenia and fatigue are 
consolidated terms (composite terms consisting of multiple 
related preferred terms) based on Standardized  MedDRA® 
Queries (SMQ) and medical review. Diarrhea was included 
as an adverse event of interest as it is one of the most fre-
quent TEAE for the FOLFIRI regimen [18, 19]. Safety end-
points were graded per the NCI-CTCAE v4.0.
Results
Data from a total of 425 patients from the ramucirumab 
plus FOLFIRI arm and 481 patients from the placebo plus 
FOLFIRI arm were included in the exposure–efficacy analy-
ses; data from a total of 425 patients from the ramucirumab 
plus FOLFIRI arm and 480 patients from the placebo plus 
FOLFIRI arm were included in the exposure–safety analy-
ses. One patient randomized to the placebo group received 
ramucirumab as the first dose and was included in the pla-
cebo plus FOLFIRI arm for exposure–efficacy analysis and 
excluded from the placebo plus FOLFIRI arm for expo-
sure–safety analysis.
An exploratory Cox regression analysis identified a sta-
tistically significant positive association between OS and 
Cmin,ss in a univariate analysis (p < 0.0001). A multivariate 
Cox regression analysis was used to adjust for the factors 
that were significantly associated with OS: time to progres-
sion after beginning first-line therapy, KRAS status, ECOG 
PS, number of metastatic sites, liver only metastasis, and 
carcinoembryonic antigen (CEA). After adjusting for these 
baseline factors, the association between OS and Cmin,ss 
remained statistically significant (p < 0.0001). Similar to 
OS, a statistically significant positive association was iden-
tified between PFS and Cmin,ss in a univariate Cox regres-
sion analysis (p < 0.0001). A multivariate Cox regression 
analysis was used to adjust for the factors that were signifi-
cantly associated with PFS: ECOG PS, number of metastatic 
sites, liver only metastasis, CEA, and prior bevacizumab use 
(composite subgroup). A similar association between ramu-
cirumab exposure and PFS was observed after adjusting for 
these significant baseline factors (p < 0.0001).
Ramucirumab concentration data from patients in the 
ramucirumab plus FOLFIRI arm were grouped into four 
Cmin,ss quartiles (<25% [Q1], 25% to <50% [Q2], 50% to 
<75% [Q3], and ≥75% [Q4]) based on the predicted Cmin,ss 
concentration. Demographic data and baseline disease 
characteristics by Cmin,ss quartile are presented in Table 1. 
Similarity in the data in Supplemental Table 2 between the 
overall study population (ITT population) [9] and the expo-
sure–response population suggests that the analyzed sub-
population is reflective of the overall population enrolled 
in RAISE.
The Kaplan–Meier plots of OS and PFS by Cmin,ss quar-
tiles are presented in Fig. 2a and b. Separation between the 
OS curves was observed among the four exposure groups, 
suggesting that higher exposure may be associated with 
longer OS time. Median OS was 11.5, 12.9, 16.4, and 
16.7 months for the ramucirumab Cmin,ss Q1, Q2, Q3, and 
Q4 groups, respectively (Table 2). Median OS in the pla-
cebo plus FOLFIRI arm was 12.4 months (Table 2). Hazard 
ratios by quartile were adjusted for baseline factors. There 
was a trend of numerically decreasing hazard ratios as the 
predicted concentration of ramucirumab Cmin,ss increased. 
Quartile 1 and Q2 were not significantly different from the 
placebo group; however, Q3 and Q4 showed hazard ratios 
favoring the ramucirumab plus FOLFIRI treatment arm 
(Table 2).
The Kaplan–Meier plots of PFS curves were similar to 
those for OS (Fig. 2b). The higher exposure groups were 
associated with longer PFS. Median PFS was 5.4, 4.6, 6.8, 
and 8.5 months for the ramucirumab Cmin,ss Q1, Q2, Q3, 
and Q4 groups, respectively (Table 2). Median PFS in the 
placebo plus FOLFIRI arm was 5.2 months (Table 2). The 
PFS hazard ratios were adjusted for baseline factors and 
decreased as the concentration of predicted ramucirumab 
Cmin,ss increased by quartile. Similar to the results for OS, 
PFS for Q1 and Q2 were not significantly different from the 
placebo group, but Q3 and Q4 demonstrated progressively 
decreasing HRs that were significantly different from the 
placebo group.
A matched case–control analysis for OS was explored to 
evaluate the exposure–OS relationship and adjust for imbal-
ances between the Cmin,ss quartiles. As previously described, 
there were eight matching factors for which outcomes were 
to be adjusted: time to progression after beginning first-line 
therapy, KRAS status, ECOG PS, number of metastatic 
sites, liver only metastasis, CEA, gender, and combined 
prior bevacizumab use (composite subgroup). Patients from 
both ramucirumab and placebo arms were included in the 
exposure–response analysis only if they did not die or dis-
continue treatment prior to Day 1 Cycle 3 and had exposure 
data (Cmin,ss) available. The matching was performed sepa-
rately for each of the four  Cmin,ss exposure quartiles (Q1–Q4) 
from the ramucirumab plus FOLFIRI arm (Supplemental 
Table 1).
To compare the two treatment arms in each of the four 
matched case–control groups, Kaplan–Meier curves for OS 
in each group are shown in Supplemental Fig. 1. Clear sepa-
ration of OS curves was observed in matched Q3 and Q4, but 
not Q1 and Q2. As compared with matched control patients, 
patients in Q3 and Q4 groups showed longer survival rela-
tive to patients in Q1 and Q2 groups. This is consistent with 
the exposure–response association as observed earlier. In 
addition, the steep dose–effect relationship depicted in Sup-
plemental Table 3 shows that the risk of death or disease 
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 <65 years 287 (59.7) 70 (66.0) 63 (59.4) 67 (63.2) 65 (60.7)
 ≥65 years 194 (40.3) 36 (34.0) 43 (40.6) 39 (36.8) 42 (39.3)
Gender
 Female 183 (38.0) 45 (42.5) 58 (54.7) 45 (42.5) 56 (52.3)
 Male 298 (62.0) 61 (57.5) 48 (45.3) 61 (57.5) 51 (47.7)
Race
 White 372 (77.3) 73 (68.9) 70 (66.0) 80 (75.5) 87 (81.3)
 Asian 92 (19.1) 26 (24.5) 31 (29.2) 22 (20.8) 18 (16.8)
 Other 13 (2.7) 5 (4.7) 5 (4.7) 4 (3.8) 2 (1.9)
 Missing 4 (0.8) 2 (1.9) 0 (0.0) 0 (0.0) 0 (0.0)
Region
 Europe 216 (44.9) 45 (42.5) 47 (44.3) 40 (37.7) 52 (48.6)
 North America 120 (24.9) 24 (22.6) 24 (22.6) 33 (31.1) 29 (27.1)
 Other 145 (30.1) 37 (34.9) 35 (33.0) 33 (31.1) 26 (24.3)
ECOG PS
 0 238 (49.5) 42 (39.6) 52 (49.1) 68 (64.2) 58 (54.2)
 1+ 243 (50.5) 63 (59.4) 54 (50.9) 37 (34.9) 48 (44.9)
 Missing 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.9) 1 (0.9)
Time to disease progression after first-line therapy
 <6 months 111 (23.1) 31 (29.2) 22 (20.8) 21 (19.8) 21 (19.6)
 ≥6 months 370 (76.9) 75 (70.8) 84 (79.2) 85 (80.2) 86 (80.4)
KRAS Status
 Mutant 234 (48.6) 52 (49.1) 48 (45.3) 59 (55.7) 57 (53.3)
 Wild-type 247 (51.4) 54 (50.9) 58 (54.7) 47 (44.3) 50 (46.7)
Number of metastatic sites
 1 146 (30.4) 35 (33.0) 41 (38.7) 29 (27.4) 28 (26.2)
 2 177 (36.8) 40 (37.7) 40 (37.7) 42 (39.6) 45 (42.1)
 ≥3 158 (32.8) 31 (29.2) 25 (23.6) 35 (33.0) 34 (31.8)
Liver only metastasis
 No 394 (81.9) 86 (81.1) 82 (77.4) 92 (86.8) 91 (85.0)
 Yes 87 (18.1) 20 (18.9) 24 (22.6) 14 (13.2) 16 (15.0)
Site of primary tumor
 Colon 318 (66.1) 58 (54.7) 63 (59.4) 82 (77.4) 71 (66.4)
 Rectal 158 (32.8) 48 (45.3) 43 (40.6) 22 (20.8) 35 (32.7)
 Colorectal 5 (1.0) 0 (0.0) 0 (0.0) 2 (1.9) 1 (0.9)
Carcinoembryonic antigen
 <200 µg/L 359 (74.6) 77 (72.6) 77 (72.6) 84 (79.2) 79 (73.8)
 ≥200 µg/L 91 (18.9) 23 (21.7) 23 (21.7) 16 (15.1) 21 (19.6)
 Missing 31 (6.4) 6 (5.7) 6 (5.7) 6 (5.7) 7 (6.5)
Time from first bevacizumab dose to last bevacizumab dose
 <3 months 88 (18.3) 13 (12.3) 15 (14.2) 14 (13.2) 13 (12.1)
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Note Patients in each exposure quartile group were a non-randomized subset of the ITT population and potential imbalances in prognostic factors 
between the placebo arm and the quartile groups may be generated due to the loss of randomization. However, the multivariate Cox regression 
analysis was adjusted for all prognostic factors significantly associated with OS or PFS
Cmin,ss minimum concentration at steady state, ECOG PS Eastern Oncology Cooperative Group performance status, FOLFIRI folinic acid, 
5-fluorouracil, and irinotecan; ITT intent-to-treat, OS overall survival, PFS progression-free survival, Q quartile





















 ≥3 months 391 (81.3) 93 (87.7) 90 (84.9) 91 (85.8) 94 (87.9)
 Missing 2 (0.4)a 0 (0.0) 1 (0.9) 1 (0.9) 0 (0.0)
Fig. 2  a  RAISE overall survival by ramucirumab  Cmin,ss exposure 
quartile. Ramucirumab  Cmin,ss quartile concentrations: Q1 (<25%) 
<49.7 µg/mL, Q2 (25% to <50%) 49.7 to <62.6 µg/mL, Q3 (50% to 
<75%) 62.6 to <81.1 µg/mL, Q4 (≥75%) ≥81.1 µg/mL. b RAISE 
progression-free survival by ramucirumab  Cmin,ss exposure quartile. 
Ramucirumab  Cmin,ss quartile sconcentrations: Q1 (<25%) <49.7 µg/
mL, Q2 (25% to <50%) 49.7 to <62.6 µg/mL, Q3 (50% to <75%) 
62.6 to <81.1 µg/mL, Q4 (≥75%) ≥81.1 µg/mL  Cmin,ss, minimum 
concentration at steady state; PBO placebo; Q quartile; RAM ramu-
cirumab
Table 2  RAISE overall survival and progression-free survival by ramucirumab exposure quartile
Cmin,ss minimum concentration at steady state, ECOG  PS Eastern Oncology Cooperative Group performance status, FOLFIRI folinic acid, 
5-fluorouracil, and irinotecan, OS overall survival, PBO placebo, PFS progression-free survival, Q quartile, RAM ramucirumab
a Adjusted for time to progression after beginning first-line therapy, KRAS status, ECOG PS, number of metastatic sites, liver only metastasis, 
and carcinoembryonic antigen
b Adjusted for ECOG PS, number of metastatic sites, liver only metastasis, carcinoembryonic antigen, and prior bevacizumab use
c Adjusted for significant prognostic factors relative to PBO + FOLFIRI in RAISE
d Wald’s test of RAM quartile versus PBO + FOLFIRI
e Median OS and PFS for PBO + FOLFIRI differ from those reported in Tabernero et al. [9], because patients in the PBO arm who dropped out 
prior to the third dose were excluded from the exposure–efficacy analyses
Quartile, Cmin,ss Overall  survivala Progression-free  survivalb
Median (mos) Hazard ratio (95% CI)c p  valued Median (mos) Hazard ratio (95% CI)c p  valued
PBO + FOLFIRI 12.4e 5.2e
RAM + FOLFIRI Q1 11.5 1.311 (1.024, 1.678) 0.0314 5.4 0.932 (0.739, 1.175) 0.5516
RAM + FOLFIRI Q2 12.9 0.954 (0.736, 1.238) 0.7249 4.6 0.957 (0.763, 1.200) 0.7013
RAM + FOLFIRI Q3 16.4 0.604 (0.459, 0.795) 0.0003 6.8 0.684 (0.542, 0.864) 0.0014
RAM + FOLFIRI Q4 16.7 0.657 (0.500, 0.865) 0.0027 8.5 0.546 (0.434, 0.688) <0.0001
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progression was reduced by approximately 40% or 30%, 
respectively, when Cmin,ss was doubled.
The percentage of patients with dose modifications (dose 
delay, dose reduction, and dose omission) or dose discon-
tinuation of ramucirumab in all four ramucirumab plus 
FOLFIRI quartiles was generally higher as compared to the 
placebo plus FOLFIRI arm (Fig. 3). Patients with higher 
ramucirumab exposure appeared to have higher incidence 
of dose delay as compared to patients with lower exposure 
(Fig. 3). The percentage of patients with dose modifications 
(dose delay, dose reduction, and dose omission) or dose 
discontinuation of FOLFIRI in all four ramucirumab plus 
FOLFIRI quartiles was generally higher as compared to 
the placebo plus FOLFIRI arm. In addition, patients with 
higher ramucirumab exposure also had higher incidence of 
dose modifications of FOLFIRI as compared to patients with 
lower exposure (Fig. 3). Higher incidence of 5-fluorouracil 
dose discontinuation was observed in patients with higher 
ramucirumab exposure. Thus, although Q4 patients had 
more dose reduction and delay, they still had superior PFS 
and OS to lower exposure quartiles.
Observed TEAE incidences (≥Grade 3) (selected safety 
endpoints for exposure–safety analysis) for both ramu-
cirumab and placebo arms were similar between the over-
all study population and the exposure–response analysis 
population (Supplemental Table 2). Incidence differences 
between ramucirumab and placebo arms were also similar 
in these two populations. Therefore, the safety data used 
in the exposure–safety analysis were judged representative 
of data obtained from the overall study population. The 
observed incidences of Grade ≥3 neutropenia, hypertension, 
fatigue, and diarrhea by concentration quartile are shown in 
Fig. 4. There were no Grade 5 TEAEs reported. For patients 
receiving ramucirumab plus FOLFIRI, neutropenia was the 
Grade ≥3 TEAE with the highest incidence in all quartiles, 
and was most frequently reported in Q4, patients with the 
highest concentration of ramucirumab. A statistically sig-
nificant (p < 0.001) relationship was only identified between 
Cmin,ss and incidence of neutropenia (Grade ≥3). Severity 
of neutropenia (Grade 3 vs Grade 4) was independent of 
exposure. Additional covariate analyses found age at study 
entry, sex, and Asian race to be significant predictors for 
risk of neutropenia in CRC patients regardless of treatment 
arm. It is of interest to note that for neutropenia, hyperten-
sion, fatigue, and diarrhea, most of the increase in toxicity 
occurred between the control and Q1 and very little increase 
in toxicity occurred between Q1 and Q4.
Discussion
In the RAISE trial, median OS and PFS were significantly 
greater for patients receiving ramucirumab plus FOLFIRI 
when compared to placebo plus FOLFIRI treatment [9]. 
Exploratory exposure–response analyses presented here 
demonstrate that longer median OS and PFS may be asso-
ciated with increasing ramucirumab exposure as seen in 
patients in higher exposure quartiles (Q3 and Q4). This rela-
tionship was demonstrated with both an unadjusted analysis 
and a matched pair analysis. These analyses suggest that the 
Fig. 3  Dose omission/dose modification by exposure-response quartile 5-FU, 5-fluorouracil, Q quartile
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observed exposure–efficacy relationship is independent of 
a patient’s baseline characteristics. Although incidence of 
≥Grade 3 neutropenia was found to be significantly cor-
related with predicted ramucirumab concentration, severity 
of neutropenia (Grade 3 vs Grade 4) was independent of 
exposure. Grade 3 or greater febrile neutropenia in the ITT 
population was low (ramucirumab: 18 patients, 3%; placebo: 
13 patients, 2%) [9] and could not be evaluated by quartile 
due to the low incidence. There was no statistically signifi-
cant relationship identified between ramucirumab exposure 
and hypertension, fatigue, or diarrhea. Thus, the analysis 
suggests that some of the toxicities seem to reach maximal 
intensity in the Q1 population and do not get worse with 
increasing exposure.
Of note, for both PFS and OS in multivariate Cox regres-
sion and the matched case–control analysis, patients in the 
two lowest exposure quartiles had no apparent benefit from 
adding ramucirumab to FOLFIRI; the benefit was seen 
in patients with higher exposure (Q3 and Q4). This steep 
dose–effect relationship shows that the risk of death or dis-
ease progression was reduced when Cmin,ss was doubled.
Although patients in the higher exposure quartiles 
appeared to have greater incidences of ramucirumab dose 
delay, there was no apparent relationship between ramu-
cirumab exposure and dose reduction, dose omission, or 
dose discontinuation of ramucirumab. Ramucirumab dose 
intensity was consistent across all four quartiles, demonstrat-
ing that a ramucirumab 8 mg/kg every-2-week dosing regi-
men is safe. Higher incidences of dose delay, dose reduction, 
dose omission, or dose discontinuation of all components 
of FOLFIRI were observed for higher exposure quartiles. 
However, despite these dose reductions and delays in the Q4 
group, they have superior PFS and OS compared to lower 
quartiles.
The development and introduction of monoclonal anti-
bodies targeting EGFR and angiogenic pathways have 
expanded treatment options for cancer patients [20–30]. 
In most cases, the dosing strategy is based on the titration 
of the drug to a tolerable dose. However, clinical phar-
macokinetics have been used to confirm the rationale for 
the recommended dose of antiangiogenic agents [31–33]. 
The current results with ramucirumab are also consistent 
with exposure–response (efficacy and safety) relationships 
observed for agents targeting tyrosine kinase inhibitors 
(TKIs). Exposure–response analyses of sunitinib, an oral 
multi-targeted receptor TKI, demonstrated that increased 
exposure is associated with longer OS, greater antitumor 
response, longer time to tumor progression, and some 
increased risk of adverse effects in patients with advanced 
tumors [34]. Similarly, greater Cmin of nilotinib, a selective 
Fig. 4  Incidence of Grade ≥3 treatment-emergent adverse events by 
ramucirumab  Cmin,ss exposure quartile. There was only one reported 
Grade 4 hypertension event, nine reported Grade 4 diarrhea events, 
and no Grade 4 fatigue events. A total of 9.4% patients reported 
Grade 4 neutropenia. There were no Grade 5 events for all four safety 
endpoints. Treatment-emergent adverse events were graded by NCI-
CTCAE v4.0. Neutropenia and fatigue are consolidated terms, mean-
ing they are a composite term consisting of multiple related preferred 
terms based on Standardized Medical Dictionary for Regulatory 
Activities (MedDRA) Queries and medical review.  Cmin,ss, minimum 
concentration at steady state; FOLFIRI, folinic acid, 5-fluoroura-
cil, and irinotecan; NCI-CTCAE National Cancer Institute-Common 
Terminology Criteria for Adverse Events; PBO placebo; Q quartile; 
RAM ramucirumab
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break point cluster-Abelson (BCR-ABL) TKI, was associ-
ated with shorter time to complete cytogenetic response, 
shorter time to major molecular response, longer time to 
progression, and a trend toward higher response rates in 
patients with chronic myeloid leukemia [35]. These results 
are also consistent with exposure–response relationships 
observed for other agents (ipilimumab, ado-trastuzumab, 
and rituximab) targeting pathways in cancer. A higher Cmin 
of ipilimumab, a fully human IgG1 monoclonal antibody 
that blocks cytotoxic T-lymphocyte antigen-4, was associ-
ated with increased tumor responses and longer survival 
in patients with advanced melanoma [10]. An association 
between Cmin levels and OS, PFS, and objective response 
rate was observed for ado-trastuzumab, a human epidermal 
growth factor 2 (HER2)–directed antibody–drug conjugate, 
in HER-2 positive metastatic breast cancer [11]. In addition, 
increased clearance of bevacizumab, a humanized monoclo-
nal IgG1 antibody that targets VEGF-A, was also associated 
with poorer prognosis for gastric cancer patients [36].
Previous analyses have demonstrated that higher pre-
dicted ramucirumab exposure was associated with longer 
OS and PFS, smaller hazard ratios, and increased but man-
ageable toxicity in patients with previously-treated advanced 
gastric or gastroesophageal cancer as well as in patients 
with metastatic non-small cell lung cancer [13, 14]. The 
ramucirumab dose of 8 mg/kg every 2 weeks regimen is a 
clinically effective and safe dose in the CRC indication and 
offers a favorable benefit-risk profile in patients with CRC. 
The present exposure–response analysis shows a positive 
relationship between efficacy and ramucirumab exposure, 
seen particularly in the upper two quartiles. This opens the 
question of whether an increased dose of ramucirumab could 
achieve higher exposure in more patients, thus increasing 
the efficacy of ramucirumab treatment while maintaining 
a tolerable safety profile. Such clinical trials are ongoing in 
gastric and gastroesophageal junction cancers: with mono-
therapy (NCT02443883) and in the combination therapy 
with paclitaxel setting (NCT02514551).
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